Death by end of trial · patients with schizophrenia
Paliperidone palmitate showed no clear difference in death Reported by trial author compared with risperidone long‐acting injection (low certainty).
1 finding from 1 review
No clinically important change Number of people whose PANSS score either increased or did not decrease by at least 30% from the beginning to the end of the trial · patients with schizophrenia
Paliperidone palmitate showed no clear difference in no clinically important change Number of people whose PANSS score… compared with risperidone long‐acting injection (low certainty).
1 finding from 1 review
Relapse: recurrence of psychotic symptoms Reported by trial author as adverse event · patients with schizophrenia
Paliperidone palmitate showed no clear difference in relapse: recurrence of psychotic symptoms Reported by trial authors… compared with risperidone long‐acting injection (moderate certainty).
1 finding from 1 review
Cost ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health related quality of life ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · patients with schizophrenia
Paliperidone palmitate showed no clear difference in leaving the study early ‐ any reason Reported by trial author compared with risperidone long‐acting injection (high certainty).
1 finding from 1 review
Leaving the study early ‐ lack of efficacy Reported by trial author · patients with schizophrenia
Paliperidone palmitate probably leads to higher leaving the study early ‐ lack of efficacy Reported by trial author compared with risperidone long‐acting injection (moderate certainty).
1 finding from 1 review
Balance ( · patients with neurodegenerative disease
1 finding from 1 review
Gait Time Up and Go test and Stand‐walk‐sit test · patients with neurodegenerative disease
1 finding from 1 review
UPDRS III UPDRS scale (motor score). Scale from: 0 to 56. · patients with neurodegenerative disease
1 finding from 1 review
Hospitalization · patients submitted to transrectal prostate biopsy
Short course showed no clear difference in hospitalization compared with long course treatment (low certainty).
1 finding from 1 review
Bacteriuria · patients submitted to transrectal prostate biopsy
Short course probably leads to higher bacteriuria compared with long course treatment (moderate certainty).
1 finding from 1 review
Fever · patients submitted to transrectal prostate biopsy
Short course showed no clear difference in fever compared with long course treatment (moderate certainty).
1 finding from 1 review
UTI · patients submitted to transrectal prostate biopsy
Short course showed no clear difference in UTI compared with long course treatment (moderate certainty).
1 finding from 1 review
All‐cause mortality
HbA1c (%)
Health‐related quality of life
HbA1c (%)
All‐cause mortality
0.14 [0, 6.98]
8 studies · 2175 participants
Moderate
Peto OR 1.06 [0.62, 1.82]
14 studies · 6173 participants
Low
Depressive symptomatology (lower = less depressive symptomatology): end‐of‐intervention · older people with depression
1 finding from 1 review